Bayesian reanalysis supports rituximab–lenalidomide non-inferiority in follicular lymphoma
A Bayesian reanalysis of the RELEVANCE trial found extremely low probabilities that rituximab plus lenalidomide was inferior to rituximab plus ...
Tag: non-inferiority
